A Study of Nimotuzumab in Combination With External Radiotherapy in Non-Small Cell Lung Cancer

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

June 30, 2011

Study Completion Date

July 31, 2011

Conditions
Non-small-cell Lung Cancer
Interventions
PROCEDURE

External radiotherapy

Radiotherapy for first 2 weeks, 10 daily fractions of 30Gy 2 additional fractions to be added if desirable

BIOLOGICAL

nimotuzumab

weekly dose until disease progression

Trial Locations (13)

34655

Florida Cancer Institute - New Hope, New Port Richey

160610

National Cancer Center Singapore, Singapore

T2N 4N2

Tom Baker Cancer Center, Calgary

V1Y 5L3

Cancer Centre for the Southern Interior, Kelowna

A1B 3V6

Dr. H. Bliss Murphy Cancer Centre, St. John's

N6A 4L6

London Regional Cancer Center, London

K1H 8L6

The Ottawa Hospital Cancer Centre, Ottawa

P7B 6V4

Thunderbay Regional hospital Center, Thunderbay

M5G 2M9

Princess Margaret Hospital, Toronto

H1T-2M4

Hopital Maisonneuve-Rosemont, Montreal

H2L 4M1

Centre Hospitalier de L'Universite de Montreal - Hôpital Notre Dame, Montreal

H3T 1E2

Segal Cancer Center - Jewish General Hospital, Montreal

G1R 2J6

Hotel Dieu Hospital, Québec

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

CIMYM BioSciences

OTHER

lead

YM BioSciences

INDUSTRY

NCT00369447 - A Study of Nimotuzumab in Combination With External Radiotherapy in Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter